BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Dizal to Present New Findings on Golidocitinib-PD-1 Combo and Sunvozertinib-Anlotinib Therapy at ELCC 2025

Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced ...

March 21, 2025 | News

TiumBio and Hansoh Pharma Gain Clinical Trial Approval in China for Merigolix in ART-Related Controlled Ovarian Stimulation

Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (con...

March 21, 2025 | News

Shanghai Henlius Secures FDA Orphan Drug Designation for HLX22 in Gastric Cancer

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for...

March 20, 2025 | News

Alphamab Oncology and CSPC’s Anti-HER2 ADC JSKN003 Secures Breakthrough Therapy Designation in China

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic...

March 19, 2025 | News

Akeso’s Penpulimab Secures NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National ...

March 18, 2025 | News

Chance Pharmaceuticals Secures New Funding to Advance Phase III Trials for CXG87 and Expand Inhalation Therapy Pipeline

Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapi...

March 18, 2025 | News

Rona Therapeutics Secures FDA IND Clearance for RN0361, Advancing RNAi Therapy for Severe Hypertriglyceridemia

Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Dru...

March 18, 2025 | News

Teva Hong Kong Partners with Kerry Pharma to Enhance Medicine Distribution Across Hong Kong, Macau, and the Greater Bay Area

Teva Hong Kong ("Teva"), has announced a strategic partnership with Kerry Pharma, the subsidiary of Kerry Logistics Network Ltd ("KLN"). Leveraging Ke...

March 17, 2025 | News

Innovent’s SYCUME® Becomes China’s First IGF-1R Antibody Approved for Thyroid Eye Disease

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

March 17, 2025 | News

BioCity Biopharmaceutics and MSD Partner to Evaluate BC3195-KEYTRUDA® Combo in Global Phase 1/2 Trial

BioCity Biopharmaceutics Co., Ltd., a clinical-stage biopharmaceutical company, announced that it has entered into a clinical trial collaboration agr...

March 14, 2025 | News

WuXi XDC and AbTis Partner to Advance Site-Selective ADC Conjugation

WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiza...

March 12, 2025 | News

Sichuan Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan Secures NMPA Approval for EGFR-Mutant NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP...

March 11, 2025 | News

Gan & Lee Initiates Phase 2 Trial of Bofanglutide, the First GLP-1 Mono-Agonist to Challenge Tirzepatide in Weight Management

Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a P...

March 11, 2025 | News

Fosun Pharma’s Foritinib Secures NMPA Nod for ALK+ NSCLC with Strong CNS Control and Improved Safety

Fosun Pharma announced that the National Medical Products Administration (NMPA) has officially accepted the marketing authorization application for Foritin...

March 10, 2025 | News

Stay Connected